Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements
Latest Information Update: 06 Jun 2025
At a glance
- Drugs Futibatinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms FOENIX-CCA4
- Sponsors Taiho Oncology
Most Recent Events
- 03 Feb 2025 Planned End Date changed from 1 Jun 2026 to 1 Dec 2026.
- 03 Feb 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.
- 20 Jan 2024 Study design presented at the 2024 Gastrointestinal Cancers Symposium.